West Pharmaceutical Services, Inc. (NYSE:WST) Shares Sold by Benjamin Edwards Inc.

Benjamin Edwards Inc. lessened its stake in West Pharmaceutical Services, Inc. (NYSE:WST) by 6.7% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 553 shares of the medical instruments supplier’s stock after selling 40 shares during the period. Benjamin Edwards Inc.’s holdings in West Pharmaceutical Services were worth $182,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its holdings in shares of West Pharmaceutical Services by 1.2% in the fourth quarter. Vanguard Group Inc. now owns 9,002,632 shares of the medical instruments supplier’s stock valued at $3,170,007,000 after purchasing an additional 104,740 shares during the period. Artisan Partners Limited Partnership increased its stake in West Pharmaceutical Services by 23.2% in the 4th quarter. Artisan Partners Limited Partnership now owns 1,961,063 shares of the medical instruments supplier’s stock valued at $690,530,000 after buying an additional 369,792 shares during the period. TD Asset Management Inc raised its position in West Pharmaceutical Services by 38.4% during the 4th quarter. TD Asset Management Inc now owns 659,560 shares of the medical instruments supplier’s stock worth $232,244,000 after buying an additional 183,153 shares during the last quarter. Findlay Park Partners LLP lifted its stake in shares of West Pharmaceutical Services by 30.6% in the 1st quarter. Findlay Park Partners LLP now owns 597,106 shares of the medical instruments supplier’s stock worth $236,281,000 after acquiring an additional 139,800 shares during the period. Finally, ProShare Advisors LLC raised its holdings in West Pharmaceutical Services by 13.9% during the first quarter. ProShare Advisors LLC now owns 500,662 shares of the medical instruments supplier’s stock worth $198,117,000 after purchasing an additional 61,247 shares in the last quarter. Institutional investors and hedge funds own 93.90% of the company’s stock.

Insider Transactions at West Pharmaceutical Services

In related news, VP Charles Witherspoon sold 1,029 shares of the firm’s stock in a transaction dated Monday, August 19th. The shares were sold at an average price of $300.00, for a total value of $308,700.00. Following the completion of the sale, the vice president now owns 1,478 shares in the company, valued at $443,400. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.53% of the company’s stock.

West Pharmaceutical Services Price Performance

Shares of NYSE:WST opened at $308.15 on Friday. The company has a quick ratio of 1.68, a current ratio of 2.34 and a debt-to-equity ratio of 0.03. The company has a 50-day moving average price of $303.37 and a 200 day moving average price of $337.31. West Pharmaceutical Services, Inc. has a 52 week low of $265.00 and a 52 week high of $413.70. The company has a market cap of $22.45 billion, a P/E ratio of 40.65, a PEG ratio of 10.58 and a beta of 1.01.

West Pharmaceutical Services (NYSE:WST) last posted its quarterly earnings results on Thursday, July 25th. The medical instruments supplier reported $1.52 earnings per share for the quarter, missing analysts’ consensus estimates of $1.74 by ($0.22). The business had revenue of $702.10 million during the quarter, compared to analysts’ expectations of $729.36 million. West Pharmaceutical Services had a net margin of 18.25% and a return on equity of 19.17%. The firm’s quarterly revenue was down 6.9% compared to the same quarter last year. During the same quarter last year, the firm earned $2.11 earnings per share. Research analysts predict that West Pharmaceutical Services, Inc. will post 6.42 earnings per share for the current year.

West Pharmaceutical Services Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.